Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2025
The Impact of Lovenox Prophylaxis and Other Anticoagulants on Microvascular Free Flap Outcomes.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bhatnagar Kavita, Smith Hannah, Taghizadeh Farshid, Young Gavin, Trott Skylar, Clayburgh Daniel, Yang Sara, Wax Mark K
Аннотация
OBJECTIVE: Microvascular free flap reconstruction for head and neck defects carries a 95% success rate. When flap compromise occurs, it is often due to vascular occlusion. This study seeks to determine what impact lovenox prophylaxis has on flap outcomes and postoperative complications.
STUDY DESIGN: A retrospective review.
SETTING: A single tertiary institution.
METHODS: A total of 1100 patients underwent microvascular free flap reconstruction from January 2010 to May 2019. The use of lovenox prophylaxis began in 2013, and by 2015, it was routinely used. Flap outcome and postoperative complications were compared between those who received postoperative lovenox prophylaxis and those who did not, using a chi-squared analysis. Outcomes among patients on therapeutic heparin and other oral anticoagulants were similarly examined.
RESULTS: There was no difference between those with (n = 716) or without chemoprophylaxis (n = 384) in rates of flap compromise (11.46% vs 12.71%), salvage (43.19% vs 52.71%), and overall failure (6.51% vs 6.01%) (P = .45). Rates of arterial insufficiency (8.07% vs 7.82%, P = .89) and venous congestion (3.39% vs 5.73%, P= .09) were equivalent. Arterial insufficiency (23.85%, P = .0002) was highest among the therapeutic heparin group. The rate of hematoma was significantly different between those without chemoprophylaxis (2.08%), and those on lovenox (3.77%), heparin (10.55%), and other anticoagulants (14.55%) (P = 4 × 10-8).
CONCLUSIONS: Lovenox prophylaxis does not appear to impact overall flap survival but does confer a small increase in hematoma risk. There were higher rates of complications among patients on therapeutic heparin. Patients who require anticoagulation for other medical comorbidities are nearly 4 times as likely to develop hematomas and should be counseled accordingly.
STUDY DESIGN: A retrospective review.
SETTING: A single tertiary institution.
METHODS: A total of 1100 patients underwent microvascular free flap reconstruction from January 2010 to May 2019. The use of lovenox prophylaxis began in 2013, and by 2015, it was routinely used. Flap outcome and postoperative complications were compared between those who received postoperative lovenox prophylaxis and those who did not, using a chi-squared analysis. Outcomes among patients on therapeutic heparin and other oral anticoagulants were similarly examined.
RESULTS: There was no difference between those with (n = 716) or without chemoprophylaxis (n = 384) in rates of flap compromise (11.46% vs 12.71%), salvage (43.19% vs 52.71%), and overall failure (6.51% vs 6.01%) (P = .45). Rates of arterial insufficiency (8.07% vs 7.82%, P = .89) and venous congestion (3.39% vs 5.73%, P= .09) were equivalent. Arterial insufficiency (23.85%, P = .0002) was highest among the therapeutic heparin group. The rate of hematoma was significantly different between those without chemoprophylaxis (2.08%), and those on lovenox (3.77%), heparin (10.55%), and other anticoagulants (14.55%) (P = 4 × 10-8).
CONCLUSIONS: Lovenox prophylaxis does not appear to impact overall flap survival but does confer a small increase in hematoma risk. There were higher rates of complications among patients on therapeutic heparin. Patients who require anticoagulation for other medical comorbidities are nearly 4 times as likely to develop hematomas and should be counseled accordingly.